Company news
Rezolute, Inc. (NASDAQ:RZLT) news
Rezolute, Inc. news releases on 6ix. Latest, Mar 22, 2021: Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
Press releases — page 3
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
March 21, 2021
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
March 7, 2021
Rezolute to Participate in Upcoming Investor Conferences in March
March 1, 2021
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
February 9, 2021
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
January 11, 2021
Rezolute Announces Change of Transfer Agent
December 27, 2020
FDA Clears Rezolute’s IND Application for RZ402
December 2, 2020
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 18, 2020
Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
October 8, 2020
Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
September 9, 2020
Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
July 26, 2020
Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
June 14, 2020
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
June 9, 2020
Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
May 31, 2020
Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
May 27, 2020
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
May 13, 2020
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
February 9, 2020
Rezolute to Present at BIO CEO & Investor Conference 2020
January 26, 2020
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
December 17, 2019
Rezolute Management to Present at 2020 Biotech Showcase Conference
December 1, 2019
Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
November 24, 2019